Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2020-05-22 Major Shareholding Noti…
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
THE SCHEDULE 13G
Major Shareholding Notification
2020-05-22 English
FORM 4 SUBMISSION
Director's Dealing
2020-05-14 English
FORM 4 SUBMISSION
Director's Dealing
2020-05-14 English
FORM 4 SUBMISSION
Director's Dealing
2020-05-14 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2020, reporting the entry into a material definitive agreement related to an underwriting agreement for a public offering of common stock. The content focuses on the details of the financing transaction, including the number of shares, price, underwriters, and use of proceeds. There are no financial statements or quarterly/yearly financial results presented. The document is a current report on a capital raising event, which fits the Capital/Financing Update category. The document length is 6661 characters, which is sufficient to contain substantive information about the financing event, not just an announcement or a brief notice. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-05-12 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and company overview. This type of document is a capital markets filing that provides updates on financing activities and share issuance. It is not a financial report, earnings release, or management discussion, but rather a detailed capital/financing update related to a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback.
2020-05-12 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.